Fulcrum Therapeutics Inc (NAS:FULC)
$ 4.79 -0.05 (-1.03%) Market Cap: 258.37 Mil Enterprise Value: 12.97 Mil PE Ratio: 0 PB Ratio: 1.00 GF Score: 50/100

Fulcrum Therapeutics Inc To Discuss Unmet Need In FSHD, REACH Trial And Key Measures Of Disease Progression Call Transcript

Mar 24, 2022 / 02:00PM GMT
Release Date Price: $19.4 (+5.15%)
Naomi Aoki
Fulcrum Therapeutics, Inc. - SVP of Corporate Communications & IR

Thank you for joining us today for Fulcrum Therapeutics KOL event on FSHD, a severe progressive and debilitating muscular dystrophy. I'm Naomi Aoki, Fulcrum's Senior Vice President of Corporate Communications and Investor Relations. Before we get started, please be reminded that we may make forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These may include statements about our future expectations and plans, clinical development milestones and financial projections. While these forward-looking statements represent our views as of today, they should not be relied upon as representing our views in the future. We may update these statements in the future, but we are not taking on the obligation to do so. Please refer to our most recent filings with the Securities and Exchange Commission for a discussion of risks, uncertainties associated with our business.

With me on today's call are 2 key opinion leaders, Dr. Nick Johnson and Dr. Jay Han as well as Bryan Stuart, our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot